top of page

NICE recommends adalimumab for hidradenitis suppurativa

The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.

Adalimumab, the first treatment option licensed for active moderate to severe HS, can help reduce the number of total inflammatory nodules and abscesses that appear by at least 50 percent, as well as reduce skin pain by a third.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page